Eyepoint Pharmaceuticals’ (EYPT) “Sector Perform” Rating Reiterated at Royal Bank Of Canada

Eyepoint Pharmaceuticals (NASDAQ:EYPT)‘s stock had its “sector perform” rating reiterated by research analysts at Royal Bank Of Canada in a note issued to investors on Tuesday,Benzinga reports. They currently have a $5.00 price objective on the stock, down from their prior price objective of $37.00. Royal Bank Of Canada’s price objective indicates a potential upside of 2.67% from the stock’s previous close.

Several other research analysts have also recently commented on EYPT. Jefferies Financial Group reduced their target price on shares of Eyepoint Pharmaceuticals to $8.00 and set a “buy” rating for the company in a report on Monday. HC Wainwright reissued a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Friday, July 17th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Eyepoint Pharmaceuticals in a report on Monday. Finally, Cantor Fitzgerald downgraded Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $36.78.

Eyepoint Pharmaceuticals Stock Performance

Shares of Eyepoint Pharmaceuticals stock opened at $4.87 on Tuesday. The business’s 50 day simple moving average is $13.10 and its 200 day simple moving average is $13.62. Eyepoint Pharmaceuticals has a 52-week low of $3.95 and a 52-week high of $19.11. The firm has a market cap of $419.84 million, a PE ratio of -1.30 and a beta of 1.76.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). The firm had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.45 million. Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. As a group, equities research analysts predict that Eyepoint Pharmaceuticals will post -3.6 EPS for the current year.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in EYPT. KBC Group NV acquired a new position in Eyepoint Pharmaceuticals during the first quarter worth $29,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Eyepoint Pharmaceuticals by 51.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock valued at $74,000 after acquiring an additional 1,358 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in Eyepoint Pharmaceuticals in the third quarter valued at $76,000. Tower Research Capital LLC TRC lifted its stake in Eyepoint Pharmaceuticals by 218.3% in the second quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock valued at $82,000 after acquiring an additional 5,967 shares during the last quarter. Finally, California State Teachers Retirement System grew its position in shares of Eyepoint Pharmaceuticals by 20.6% in the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock valued at $85,000 after acquiring an additional 794 shares during the period. 99.41% of the stock is owned by institutional investors.

Trending Headlines about Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: EyePoint said DURAVYU was non-inferior to on-label aflibercept in an ad hoc analysis that excluded an asymmetric cohort of nine patients whose vision loss was considered unrelated to wet AMD. The trial also showed a 42% reduction in treatment burden, strong anatomic control through Week 56, supplement-free treatment rates and a favorable redosing safety profile. EyePoint Announces Topline Data from LUGANO
• Positive Sentiment: Jefferies lowered its price target to $8 but maintained a “buy” rating, while Chardan reaffirmed its “buy” rating and $65 target. These bullish views indicate some analysts believe the LUGANO result may be addressable and that DURAVYU’s longer-duration treatment profile retains value.
• Neutral Sentiment: Trading in EYPT was temporarily halted for pending news before the trial results were released, reflecting the material importance of the announcement. JPMorgan reaffirmed its “neutral” rating.
• Negative Sentiment: The full trial dataset did not meet the primary endpoint because the unusual vision-loss cohort affected the result. Investors now face greater regulatory and clinical uncertainty, particularly while awaiting the second pivotal Phase 3 trial. EyePoint’s eye drug misses main goal in late-stage trial
• Negative Sentiment: Cantor Fitzgerald downgraded EyePoint from “overweight” to “neutral.” The setback prompted speculation that competing ophthalmology companies, including Ocular Therapeutix and Forma Therapeutics, may now appear more attractive, further pressuring EYPT’s valuation.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.